Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab combinations versus daratumumab + pomalidomide + dexamethasone in relapsed or refractory multiple myeloma
NL-OMON59614Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of talquetamab, daratumumab, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Feb 2023; status: active, not recruiting.
02
Drugs
talquetamabdaratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59614.